Illumina, Inc. (ILMN) recently acquired Fluent BioSciences, a developer of innovative single-cell technology. This strategic acquisition marks a significant step in Illumina's expansion within the single-cell research domain, aligning with the company’s broader multiomics growth strategy.The acquisition was completed on Jul 9 and funded with cash on hand. However, other financial terms of the deal were not disclosed.Enhancing Single-Cell Research CapabilitiesFluent BioSciences has developed a highly differe ...

"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."Fluent's single-cell analysis technology eliminates the need ...

Key TakeawaysIllumina said it would take a $1.47 billion goodwill impairment charge related to its spinoff of cancer testing company GRAIL.Illumina also said it would take a $420 million charge for GRAIL's in-process R&D.Illumina's purchase of GRAIL prior to regulatory approval had been steeped in controversy for years. The breakup with GRAIL (GRAL) was costly for Illumina (ILMN). The gene sequencing company wrote in a regulatory filing Thursday that it would take a $1.47 billion goodwill impairment charge ...

Tatsiana Volkava/iStock via Getty Images Investment Overview - Illumina Says Goodbye To GRAIL, & It's Worst Ever Business Decision This week, Illumina (NASDAQ:ILMN), the San Diego, California-based gene sequencing giant, brought an end to a disastrous chapter in its relatively short history by completing the divestiture of GRAIL, the cancer testing business it helped to found. The GRAIL saga has run and run, and ultimately, played a significant role in destroying the value of Illumina stock. As I wrote in a ...

(Photo credit should read CFOTO/Future Publishing via Getty Images)Future Publishing via Getty ImagesOn June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84. On the other ...

Following three years of nonstop regulatory hassles, Illumina (ILMN) finally gave up on GRAIL, leading to the successful completion of its spin-off yesterday. Following the announcement, shares of Illumina rose 1.5% at yesterday’s close and also edged up 0.1% during the after-hour trading session.With the divestment now complete, GRAIL will start trading publicly on Nasdaq from Jun 25 under the ticker symbol "GRAL." Illumina will continue to operate its legacy business independently under the ticker symbol ...

The world of biotech stocks got a new member today. Grail (NASDAQ:GRAL) has successfully completed its spinoff from industry leader Illumina (NASDAQ:ILMN). Previously, Grail had functioned as the company’s cancer-testing unit. However, after regulatory pressure, Illumina, known for its advances in the field of DNA sequencing, opted for the spinoff that would allow Grail to function as its own separate entity. Today, GRAL stock begins trading on the Nasdaq in what could be one of the summer’s hottest market ...

文章核心观点 - 公司成功完成GRAIL的分拆 [1][6] - GRAIL将于6月25日开始在纳斯达克交易所以"GRAL"代码进行常规交易 [1][7] - 公司将保留GRAIL 14.5%的股权 [2] - 公司将于8月6日发布2024年第二季度财报,并于8月13日举行战略更新会议 [3] 公司相关 - 公司通过向股东分配GRAIL股票的方式完成了GRAIL的分拆 [6][7] - 公司保留了GRAIL 14.5%的股权,并将继续为GRAIL提供测序技术、端到端工作流程和一系列服务 [2] - 公司为GRAIL分拆融资7.5亿美元,借款利率约为6.70% [4][5] GRAIL相关 - GRAIL是一家致力于早期癌症检测的医疗保健公司 [13] - GRAIL的目标是利用下一代测序、大规模临床研究和先进的机器学习技术,检测和识别多种致命性癌症的早期阶段 [13] - GRAIL的靶向甲基化平台可支持筛查和精准肿瘤学的全程护理,包括对有症状患者的多癌种早期检测、风险分层、微小残留疾病检测、生物标志物分型、治疗和复发监测 [13]

Illumina, Inc. (ILMN) has progressed in genomic research with the recent launch of DRAGEN v4.3. This is the latest version of the company’s DRAGEN software line.This new release marks a significant advancement in the field of next-generation sequencing (NGS), featuring an advanced multigenome mapping technology. This innovation allows for the inclusion of 128 samples from 26 different ancestries, thus capturing a broader spectrum of genetic diversity and reducing ancestry bias.The ability to create custom D ...

(Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesOn June 3, 2024, Illumina’s (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on the timeline.Earlier on May 6, 2024, ILMN had filed the initial Form 10 disclosing the deal overview and separation agreement. Subsequently, on June 3, 2024, ILMN submitted an amended Form 10 d ...